Avis de sécurité sur les produits de santé
Avis de sécurité sur les produits de santé au Canada et d’autres pays.
Pays
* Les informations sont disponibles en anglais seulement.
⇡ Canada
Santé Canada – Rappels et avis de sécurité
Autres ressources
- InfoVigilance sur les produits de santé
- Quoi de neuf – MedEffet Canada
- Bulletins de l’ISMP Canada
- Médicaments sécuritaires (en anglais seulement)
- Registre des médicaments et des produits de santé
- Signaler un effet secondaire
- Capsules Rx – Avis de Santé Canada (connection requise)
⇡ États-Unis
⇡ France
⇡ Royaume-Uni
- Prescribers and dispensers should use caution if switching patients between different metolazone preparations as the rate and extent of absorption of metolazone are formulation dependent. This can impact the bioavailability …
- Premature puberty and genital enlargement have been reported in children who were in close physical contact with an adult using topical testosterone and who were repeatedly accidentally exposed to this medicine. To reduce th…
- We ask healthcare professionals to be vigilant to adverse incidents involving software, apps, and artificial intelligence (AI) as medical devices and to report incidents to us via the Yellow Card scheme.
- Recent information relating to COVID-19 vaccines and medicines that has been published since the December 2022 issue of Drug Safety Update, up to 23 January 2022.
- A summary of recent letters and notifications sent to healthcare professionals about medicines.
- In view of data showing ongoing exposure to valproate in pregnancy, this article reminds healthcare professionals of the risks in pregnancy and the current Pregnancy Prevention Programme requirements, and provides informatio…
- Recent information relating to COVID-19 vaccines and medicines that has been published since the November 2022 issue of Drug Safety Update, up to 8 December 2022.
- A summary of recent letters and notifications sent to healthcare professionals about medicines.
- Healthcare professionals prescribing dupilumab should be alert to the risks of ocular reactions. New onset or worsening ocular symptoms require prompt review. Referral for ophthalmological examination should be made as appro…
- The MHRA is reviewing its approach to engaging with healthcare professionals on the safety of medicines and medical devices. Through our consultation, you can provide your views and help inform our new approach.
⇡ Nouvelle-Zélande
- Goserelin (Teva) 3.6mg and 10.8 mg implants and reports of issues when administering this medicine
- Myocarditis and pericarditis have been reported with Nuvaxovid (Novavax COVID-19 Vaccine)
- Recall of KetoSens Test Strips – batch UJ03PBXNG
- Update – Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)
- Abnormal uterine bleeding and oral anticoagulants (blood thinners)
- Medsafe is publishing a warning that the product Nhan Sam Tuyet Lien Truy Phong Hoan should not be consumed
- Accuretic found to contain nitrosamines
- Typographical error in Healgen Rapid COVID-19 Antigen Self-Test (RATs) patient instruction leaflet
- Reminder: Miracle Mineral Solution has dangerous and potentially life-threatening side effects
- Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)